{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1142.60",
  "meta" : {
    "versionId" : "9",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "SAMHSA Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-05-22"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2016-09-09"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.60",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1142.60"
    }
  ],
  "version" : "20160909",
  "name" : "C2SHIVAIDSInformationSensitivity",
  "title" : "C2S HIV/AIDS information Sensitivity",
  "status" : "active",
  "experimental" : false,
  "date" : "2016-09-09T01:00:03-04:00",
  "publisher" : "SAMHSA Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This value set is intended for use by organizations exchanging personally identifiable protected health information to perform data segmentation based on personal patient privacy preferences in the event individuals choose not to share their sensitive information. These value sets are drawn from terminology standards required for Meaningful Use certification of Electronic Health Record (EHR) systems. This type of reference information is intended to assist the implementers of interoperable EHR systems and health information exchange systems to identify and create business rules regarding the exchange and use of information identified as sensitive by jurisdictional privacy policies (e.g. state policies, 43 CFR Part 2, Title 38).),(Data Element Scope: This value set is intended to apply to disorders related to HIV/AIDS),(Inclusion Criteria: SNOMED CT codes gleaned from the SNOMED CT to ICD-10 map that is released on 31 January and 31 July of each calendar year as a derivative of SNOMED CT International.),(Exclusion Criteria: Complete set of current LOINC, RxNorm and HCPCS and CPT)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "concept" : [
          {
            "code" : "0575F",
            "display" : "HIV RNA control plan of care, documented (HIV)"
          },
          {
            "code" : "3292F",
            "display" : "HIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr)"
          },
          {
            "code" : "3490F",
            "display" : "History of AIDS-defining condition (HIV)"
          },
          {
            "code" : "3491F",
            "display" : "HIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV)"
          },
          {
            "code" : "3492F",
            "display" : "History of nadir CD4+ cell count <350 cells/mm3 (HIV)"
          },
          {
            "code" : "3493F",
            "display" : "No history of nadir CD4+ cell count <350 cells/mm3 and no history of AIDS-defining condition (HIV)"
          },
          {
            "code" : "3494F",
            "display" : "CD4+ cell count <200 cells/mm3 (HIV)"
          },
          {
            "code" : "3495F",
            "display" : "CD4+ cell count 200 - 499 cells/mm3 (HIV)"
          },
          {
            "code" : "3496F",
            "display" : "CD4+ cell count >500 cells/mm3 (HIV)"
          },
          {
            "code" : "3497F",
            "display" : "CD4+ cell percentage <15% (HIV)"
          },
          {
            "code" : "3498F",
            "display" : "CD4+ cell percentage >15% (HIV)"
          },
          {
            "code" : "3500F",
            "display" : "CD4+ cell count or CD4+ cell percentage documented as performed (HIV)"
          },
          {
            "code" : "3502F",
            "display" : "HIV RNA viral load below limits of quantification (HIV)"
          },
          {
            "code" : "3503F",
            "display" : "HIV RNA viral load not below limits of quantification (HIV)"
          },
          {
            "code" : "3510F",
            "display" : "Documentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD)"
          },
          {
            "code" : "3511F",
            "display" : "Chlamydia and gonorrhea screenings documented as performed (HIV)"
          },
          {
            "code" : "3512F",
            "display" : "Syphilis screening documented as performed (HIV)"
          },
          {
            "code" : "3513F",
            "display" : "Hepatitis B screening documented as performed (HIV)"
          },
          {
            "code" : "3514F",
            "display" : "Hepatitis C screening documented as performed (HIV)"
          },
          {
            "code" : "3515F",
            "display" : "Patient has documented immunity to Hepatitis C (HIV)"
          },
          {
            "code" : "4149F",
            "display" : "Hepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD)"
          },
          {
            "code" : "4270F",
            "display" : "Patient receiving potent antiretroviral therapy for 6 months or longer (HIV)"
          },
          {
            "code" : "4271F",
            "display" : "Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV)"
          },
          {
            "code" : "4274F",
            "display" : "Influenza immunization administered or previously received (HIV) (P-ESRD)"
          },
          {
            "code" : "4276F",
            "display" : "Potent antiretroviral therapy prescribed (HIV)"
          },
          {
            "code" : "4279F",
            "display" : "Pneumocystis jiroveci pneumonia prophylaxis prescribed (HIV)"
          },
          {
            "code" : "4280F",
            "display" : "Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV)"
          },
          {
            "code" : "4290F",
            "display" : "Patient screened for injection drug use (HIV)"
          },
          {
            "code" : "4293F",
            "display" : "Patient screened for high-risk sexual behavior (HIV)"
          },
          {
            "code" : "86689",
            "display" : "Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)"
          },
          {
            "code" : "86701",
            "display" : "Antibody; HIV-1"
          },
          {
            "code" : "86702",
            "display" : "Antibody; HIV-2"
          },
          {
            "code" : "86703",
            "display" : "Antibody; HIV-1 and HIV-2, single result"
          },
          {
            "code" : "87389",
            "display" : "Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result"
          },
          {
            "code" : "87390",
            "display" : "Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1"
          },
          {
            "code" : "87391",
            "display" : "Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-2"
          },
          {
            "code" : "87534",
            "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique"
          },
          {
            "code" : "87535",
            "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed"
          },
          {
            "code" : "87536",
            "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed"
          },
          {
            "code" : "87537",
            "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique"
          },
          {
            "code" : "87538",
            "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed"
          },
          {
            "code" : "87539",
            "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed"
          },
          {
            "code" : "87900",
            "display" : "Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics"
          },
          {
            "code" : "87901",
            "display" : "Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions"
          },
          {
            "code" : "87903",
            "display" : "Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested"
          },
          {
            "code" : "87904",
            "display" : "Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure)"
          },
          {
            "code" : "87906",
            "display" : "Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:7f8a3e9d-4aa6-4940-b9ee-7e105de4e113",
    "timestamp" : "2024-06-14T11:40:39-04:00",
    "total" : 47,
    "contains" : [
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "0575F",
        "display" : "HIV RNA control plan of care, documented (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3292F",
        "display" : "HIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3490F",
        "display" : "History of AIDS-defining condition (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3491F",
        "display" : "HIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3492F",
        "display" : "History of nadir CD4+ cell count <350 cells/mm3 (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3493F",
        "display" : "No history of nadir CD4+ cell count <350 cells/mm3 and no history of AIDS-defining condition (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3494F",
        "display" : "CD4+ cell count <200 cells/mm3 (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3495F",
        "display" : "CD4+ cell count 200 - 499 cells/mm3 (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3496F",
        "display" : "CD4+ cell count >=500 cells/mm3 (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3497F",
        "display" : "CD4+ cell percentage <15% (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3498F",
        "display" : "CD4+ cell percentage >=15% (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3500F",
        "display" : "CD4+ cell count or CD4+ cell percentage documented as performed (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3502F",
        "display" : "HIV RNA viral load below limits of quantification (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3503F",
        "display" : "HIV RNA viral load not below limits of quantification (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3510F",
        "display" : "Documentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3511F",
        "display" : "Chlamydia and gonorrhea screenings documented as performed (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3512F",
        "display" : "Syphilis screening documented as performed (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3513F",
        "display" : "Hepatitis B screening documented as performed (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3514F",
        "display" : "Hepatitis C screening documented as performed (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "3515F",
        "display" : "Patient has documented immunity to Hepatitis C (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4149F",
        "display" : "Hepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4270F",
        "display" : "Patient receiving potent antiretroviral therapy for 6 months or longer (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4271F",
        "display" : "Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4274F",
        "display" : "Influenza immunization administered or previously received (HIV) (P-ESRD)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4276F",
        "display" : "Potent antiretroviral therapy prescribed (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4279F",
        "display" : "Pneumocystis jiroveci pneumonia prophylaxis prescribed (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4280F",
        "display" : "Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4290F",
        "display" : "Patient screened for injection drug use (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "4293F",
        "display" : "Patient screened for high-risk sexual behavior (HIV)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "86689",
        "display" : "Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "86701",
        "display" : "Antibody; HIV-1"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "86702",
        "display" : "Antibody; HIV-2"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "86703",
        "display" : "Antibody; HIV-1 and HIV-2, single result"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87389",
        "display" : "Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87390",
        "display" : "Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87391",
        "display" : "Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-2"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87534",
        "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87535",
        "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87536",
        "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87537",
        "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87538",
        "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87539",
        "display" : "Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87900",
        "display" : "Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87901",
        "display" : "Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87903",
        "display" : "Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87904",
        "display" : "Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure)"
      },
      {
        "system" : "http://www.ama-assn.org/go/cpt",
        "version" : "2024",
        "code" : "87906",
        "display" : "Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)"
      }
    ]
  }
}
